Migraine and Headaches: A Comprehensive Clinical Pharmacology Review

Every year, more than 1.5 billion people worldwide suffer from migraine, a neurological disorder that can incapacitate work, school, and social life. A 2018 study found that 12 % of the U.S. population reports migraine‑related disability, costing the economy roughly $20 billion annually in lost productivity. In the emergency department, a 2019 cohort of 3,000 patients revealed that 28 % were admitted for refractory migraine, underscoring the clinical urgency of effective, evidence‑based management.

Introduction and Background

Migraine is a complex, neurovascular disorder characterized by throbbing headache, nausea, photophobia, and phonophobia. Historically, the term “migraine” derives from the Greek *hemorrhoia*, reflecting early beliefs that the disorder involved bleeding. Modern neuroscience has clarified that migraine involves the trigeminovascular system, cortical spreading depression, and neurogenic inflammation. Epidemiologically, migraine affects up to 15 % of adults, with a higher prevalence in females (2:1 ratio) and a peak incidence in the 20‑40 year age group. The condition is subdivided into migraine with aura, migraine without aura, chronic migraine (≥15 headache days/month), and medication‑overuse headache.

Pharmacologically, migraine treatment spans acute, preventive, and abortive therapies. Acute agents include non‑steroidal anti‑inflammatory drugs (NSAIDs), triptans (5‑HT1B/1D agonists), ergot derivatives, and the newer CGRP receptor antagonists (gepants) and ditans (5‑HT1F agonists). Preventive medications comprise beta‑blockers, calcium‑channel blockers, antiepileptics (topiramate, valproate), tricyclic antidepressants, and monoclonal antibodies targeting CGRP or its receptor. Each class targets distinct pathophysiologic nodes, from vascular constriction to neurotransmitter release.

Mechanism of Action

Triptans – 5‑HT1B/1D Receptor Agonists

Triptans bind to 5‑HT1B receptors on cranial blood vessels, inducing vasoconstriction, and to 5‑HT1D receptors on trigeminal nerve terminals, inhibiting CGRP release. The downstream effect is a reduction in neurogenic inflammation and pain transmission. For example, sumatriptan’s affinity for 5‑HT1B/1D (Ki ≈ 3 nM) leads to rapid onset (<15 min) and a therapeutic window of 2–3 hours for most patients.

Ergot Alkaloids – 5‑HT1B/1D/5‑HT2 Receptor Partial Agonists

Ergot derivatives (e.g., dihydroergotamine) exhibit broader receptor activity, including partial agonism at 5‑HT2 receptors, which may contribute to vasoconstriction but also to side effects such as nausea and paresthesia.

NSAIDs – COX Inhibition and Prostaglandin Suppression

NSAIDs inhibit cyclooxygenase‑1 and -2, decreasing prostaglandin synthesis. Prostaglandins sensitize peripheral nociceptors and promote vasodilation; thus, COX inhibition reduces peripheral pain amplification and central sensitization.

CGRP Receptor Antagonists (Gepants)

Gepants (ubrogepant, rimegepant, atogepant) competitively inhibit the CGRP receptor on trigeminal neurons and vascular smooth muscle. By blocking CGRP signaling, they prevent vasodilation and neurogenic inflammation without inducing vasoconstriction, making them suitable for patients with cardiovascular risk.

Ditans – 5‑HT1F Agonists

Lasmiditan selectively activates 5‑HT1F receptors on trigeminal neurons, reducing CGRP release without affecting vascular tone. This profile mitigates the cardiovascular contraindications associated with triptans.

Clinical Pharmacology

Pharmacokinetics

• Absorption – Sumatriptan: oral bioavailability 30 %; intranasal 50 %; subcutaneous 100 %. Ubrogepant oral bioavailability 70 % with peak plasma concentration (Tmax) at 1 h.

• Distribution – Volume of distribution (Vd) for sumatriptan ≈ 0.7 L/kg; for ubrogepant ≈ 0.4 L/kg. Both cross the blood‑brain barrier minimally.

• Metabolism – Sumatriptan metabolized by monoamine oxidase A (MAO‑A) to sumatriptan N‑oxide. Ubrogepant primarily via CYP3A4 and CYP2D6.

• Excretion – Sumatriptan: 70 % renal, 30 % fecal. Ubrogepant: 60 % renal, 20 % fecal.

Pharmacodynamics

• Therapeutic window: 2–3 hours for triptans; 4–6 hours for gepants.

• Dose‑response: Sumatriptan 6 mg (oral) yields 67 % pain freedom at 2 h; 12 mg increases to 73 % but with higher nausea incidence.

• Ceiling effect: For gepants, 10 mg ubrogepant provides ~70 % pain freedom; higher doses yield diminishing returns.

Therapeutic Applications

• Acute Migraine – FDA‑approved triptans (sumatriptan, rizatriptan, zolmitriptan), NSAIDs (ibuprofen, naproxen), gepants (ubrogepant, rimegepant), ditans (lasmiditan).

• Preventive Therapy – Beta‑blockers (propranolol, metoprolol), calcium‑channel blockers (verapamil), antiepileptics (topiramate, valproate), tricyclic antidepressants (amitriptyline), CGRP monoclonal antibodies (erenumab, fremanezumab, galcanezumab, eptinezumab).

• Off‑Label Uses – Triptans for cluster headaches; gepants for medication‑overuse headache; CGRP antibodies for chronic migraine despite inadequate response to oral preventives.

• Special Populations – Pediatric: sumatriptan 1 mg/kg (max 6 mg) orally; older adults: dose adjustments for renal impairment. Pregnancy: NSAIDs contraindicated after 20 weeks; triptans considered category B but used cautiously. Lactation: limited data; generally avoid triptans.

Adverse Effects and Safety

Common side effects and approximate incidence:

• Sumatriptan: nausea (25 %), flushing (15 %), paresthesia (10 %).

• NSAIDs: dyspepsia (20 %), GI bleeding (2 % with chronic use).

• Gepants: nausea (12 %), dizziness (8 %).

• Lasmiditan: somnolence (15 %), dizziness (10 %).

Serious Warnings

• Triptans: contraindicated in vasospastic disease, uncontrolled hypertension, coronary artery disease.

• NSAIDs: risk of renal impairment, GI ulceration, cardiovascular events.

• Gepants: potential for liver enzyme elevation; monitor ALT/AST in patients with hepatic disease.

• Lasmiditan: risk of serotonin syndrome when combined with MAO inhibitors.

Drug Interactions

Monitoring

• Baseline CBC, CMP, lipid panel for preventive agents.

• Liver function tests for gepants and CGRP antibodies.

• Blood pressure monitoring for beta‑blockers.

Contraindications

• Sumatriptan: active coronary disease, uncontrolled hypertension.

• NSAIDs: peptic ulcer disease, severe renal impairment.

• Gepants: severe hepatic impairment (Child‑Pugh C).

• Lasmiditan: MAO inhibitor use, severe hepatic disease.

Clinical Pearls for Practice

• “First‑Hour Rule” – For triptans, administer within 1 hour of headache onset to maximize pain freedom.

• “CGRP vs. Triptan” – Use gepants in patients with cardiovascular risk or contraindications to triptans.

• “Preventive Selection” – Beta‑blockers are first‑line for migraine with hypertension; topiramate preferred for weight‑neutral alternatives.

• “Pregnancy Safety” – NSAIDs avoided after 20 weeks; consider acetaminophen or low‑dose sumatriptan if necessary.

• “Medication‑Overuse Headache” – Discontinue acute agents for 3–4 weeks and initiate preventive therapy.

• “Mnemonic: TRIPTA” – T = Triptans, R = Receptor agonists, I = Intranasal, P = Pain freedom, T = Timing, A = Avoidance of vasoconstrictors.

Comparison Table

Exam‑Focused Review

Common stem: A 32‑year‑old woman with episodic throbbing headache improves after taking a 6 mg oral sumatriptan. Which receptor subtype is primarily responsible for this effect? Answer: 5‑HT1B/1D.

Students often confuse CGRP antagonists with triptans. Key differentiator: triptans cause vasoconstriction; gepants do not.

Must‑know facts:

• Triptans contraindicated in coronary artery disease.

• Gepants are indicated for patients with cardiovascular risk.

• Beta‑blockers are first‑line preventive agents for migraine with hypertension.

• CGRP monoclonal antibodies require subcutaneous injection and are used for refractory chronic migraine.

Key Takeaways

1. Migraine is a neurovascular disorder with high global prevalence and significant socioeconomic impact.

2. Acute therapy options include NSAIDs, triptans, gepants, and ditans, each targeting distinct pathophysiologic pathways.

3. Triptans act via 5‑HT1B/1D receptors, causing vasoconstriction and CGRP inhibition.

4. Gepants block CGRP receptors without vasoconstriction, making them suitable for patients with cardiovascular disease.

5. Lasmiditan selectively activates 5‑HT1F receptors, avoiding vascular effects.

6. Preventive agents encompass beta‑blockers, calcium‑channel blockers, antiepileptics, antidepressants, and CGRP monoclonal antibodies.

7. Safety monitoring includes renal, hepatic, and cardiovascular parameters, especially for triptans and NSAIDs.

8. Clinical pearls emphasize timing, contraindication avoidance, and appropriate drug selection based on comorbidities.

9. Exam questions often test receptor targets, drug classes, and contraindications.

10. Effective migraine management requires individualized therapy, patient education, and monitoring for adverse effects.

Always consider the patient’s cardiovascular profile and medication burden before initiating acute migraine therapy to minimize serious adverse events.